News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

InflaRx Announces Successful Closing Of Its Round B Financing



7/17/2014 10:53:50 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

JENA, Germany--(BUSINESS WIRE)--InflaRx announced today the successful closing of its round B financing by completing the second of two tranches within this round. All current investors as well as new private investors participated in this financing round B reaching an investment volume in the double digit million Euro space. The proceeds of this round will enable clinical phase II development of IFX-1, the first-in-class anti complement lead drug monoclonal antibody, in different acute inflammatory indications. In addition, the company explained that this funding shall foster pre-clinical development of IFX-2 as follow on antibody for the treatment of selected chronic inflammatory diseases and enable the development of a new bedside complement activation test in collaboration with a diagnostic partner.

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com


comments powered by Disqus
InflaRx
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES